Putting neoplasia risks attributed to immunomodulators and biologics into perspective and what to do if a malignancy develops

Charles Brenner, PhD, director of the Obesity Initiative at the University of Iowa, discusses properties of nicotinamide riboside that have been uncovered since its initial discovery in 2004.

Greg Mattingly, MD, Associate Clinical Professor, Washington University, St. Louis, Missouri, discusses needs that remain unmet in the treatment of depression.

Michael Banks, MD, discusses the results of a 2016 study that suggested that nasal spray might not be an effective vaccination tool.